SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
HALO reported Q3 2026 results. The stock moved -15.7% on the print.
HALOearnings

Earnings reactions, page 5

Halozyme Therapeutics, Inc. (HALO) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $493.0 million, an increase of 39% compared to the third quarter of 2025.
  • Royalty revenue was $341.0 million, an increase of 44% compared to $236.0 million in the third quarter of 2025.
  • GAAP diluted earnings per share was $2.01, compared to $1.43 in the third quarter of 2025.
  • Non-GAAP diluted earnings per share was $2.39, compared to $1.72 in the third quarter of 2025.
  • Operating income was $295.0 million, compared to $217.9 million in the third quarter of 2025.
  • Adjusted EBITDA was $336.2 million, compared to $248.2 million in the third quarter of 2025.

Guidance

  • Total revenue of $1.860 billion to $1.925 billion, representing growth of 33% to 38% over 2025 total revenue.
  • Revenue from royalties of $1.235 billion to $1.255 billion, representing growth of 42% to 45% over 2025.
  • Adjusted EBITDA of $1.240 billion to $1.290 billion, representing growth of 89% to 96% over 2025.
  • Non-GAAP diluted earnings per share of $8.75 to $9.05, representing growth of 111% to 118% over 2025.

Price and volatility reaction

The stock moved -15.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -9.5 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release122.962026-11-05
Close after release103.632026-11-06
Realised move-15.7%close to close
30d ATM IV change-9.5 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →